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The chemokine sink hypothesis pertaining to eryth-
rocyte Duffy Antigen Receptor for Chemokines
(DARC) during inflammation has received consider-
able attention, but lacks direct in vivo evidence.
Here we demonstrate, using mice with a targeted
deletion in CXCL5, that CXCL5 bound erythrocyte
DARC and impaired its chemokine scavenging in
blood. CXCL5 increased the plasma concentrations
of CXCL1 and CXCL2 in part through inhibiting
chemokine scavenging, impairing chemokine gradi-
ents and desensitizing CXCR2, which led to de-
creased neutrophil influx to the lung, increased lung
bacterial burden and mortality in an Escherichia coli
pneumonia model. In contrast, CXCL5 exerted
a predominant role in mediating neutrophil influx to
the lung during inflammation after LPS inhalation.
Platelets and lung resident cells were the sources
of homeostatic CXCL5 in blood and inflammatory
CXCL5 in the lung respectively. This study presents
a paradigm whereby platelets and red cells alter
chemokine scavenging and neutrophil-chemokine
interaction during inflammation.
INTRODUCTION
The Duffy Antigen Receptor for Chemokines (DARC) is a promis-
cuoussilent receptor, highly expressedonerythrocytes andpost-
capillary venules, which binds at least 16 proinflammatory CXC
and CC chemokines (Borroni et al., 2008; Gardner et al., 2004;
Horuk et al., 1993). DARC lacks the motif to enable G protein
coupling and signaling(Hadley and Peiper, 1997), and its expres-
sion on erythrocytes has been hypothesized tomodulate chemo-
kine bioavailability by acting both as a chemokine sink (Darbonne
et al., 1991) and as a reservoir (Fukumaet al., 2003). Recently, the106 Immunity 33, 106–117, July 23, 2010 ª2010 Elsevier Inc.chemokine sink hypothesis has fallen into disfavor (Horne and
Woolley, 2009), based on observations that only minimal degra-
dation of internalized DARC-associated chemokines occurs
(Pruenster et al., 2009). Furthermore, endothelial DARC has other
functions, including roles in not only unidirectional chemokine
transcytosis from the basolateral to the apical side (Pruenster
andRot, 2006), but also surface retentionof transcytosedchemo-
kines. These functions appear to facilitate chemokine-mediated
leukocyte migration across the endothelial barrier (Pruenster
et al., 2009). In this context, studies from three independently
generated DARC-deficient mouse strains show that DARC plays
a role in neutrophil trafficking to tissues during inflammation, but
its exact role in neutrophil influx into tissues remains conflicting
(Dawson et al., 2000; Luo et al., 2000; Reutershan et al., 2009;
Zarbocket al., 2007). So far, there is nodirect evidence fromthese
Darc/mice that erythrocyteDARCscavenges proinflammatory
chemokines in vivoduring inflammation, and its role as a ‘‘chemo-
kine sink’’ during such states remains contentious.
ELR (Glutamic acid-leucine-arginine)+ CXC chemokines
constitute a family of ligands essential for neutrophil influx into
inflamed tissues (Kobayashi, 2006). In mice, four members
have been identified to have neutrophil chemoattractant
activities, but whether they serve distinct or redundant roles in
inflammation and infection is not fully understood. The four
chemokines, keratinocyte-derived chemokines (KC, also named
CXCL1), macrophage inflammatory protein-2 (MIP-2, also
named CXCL2), lipopolysaccharide-induced CXC chemokine
(LIX, also named CXCL5), and lungkine (also named CXCL15)
all interact with CXCR2, the only functional receptor mediating
their chemotactic activity inmice. CXCL1 andCXCL2 have previ-
ously been suggested to be the two most important chemokines
for neutrophil recruitment into the lung in rodents (Frevert et al.,
1995; Olson and Ley, 2002; Reutershan and Ley, 2004; Schmal
et al., 1996), andCXCL15 (expressed bybronchial epithelial cells)
may play a role in pulmonary host defense against Klebsiella
pneumoniae infection (Chen et al., 2001; Rossi et al., 1999). In
contrast, the role of CXCL5 during lung inflammation is unknown.
Human CXCL5, also known as epithelial cell-derived neutro-
phil-activating peptide-78 (ENA-78), has been found to be
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2003, 2007; Zineh et al., 2008). We have previously shown that
murine CXCL5 is upregulated in the lung and expressed by alve-
olar type II epithelial (AE II) cells in response to LPS stimulation
(Jeyaseelan et al., 2005a), while CXCL1 and CXCL2 are
expressed by alveolar macrophages. Support for a functional
role of CXCL5 came from experiments in which anti-CXCL5
antibodies attenuated LPS-induced neutrophil accumulation in
the lung (Jeyaseelan et al., 2004).
To explore the physiological role of CXCL5 in regulating
neutrophil recruitment to the lung, we generated CXCL5-defi-
cient mice and determined its role in pulmonary inflammation
consequent to LPS inhalation, and host defense in a model of
murine E. coli pneumonia. In response to E. coli, CXCL5
decreased neutrophil influx to the lung and increased lung
bacterial burden, despite its known role as a neutrophil chemo-
attractant. While CXCL1 and CXCL2 are the dominant
chemotactic factors released in this model, CXCL5 inhibited
scavenging of these chemokines, at least in part through binding
to erythrocyte DARC, contributing to high concentrations of
CXCL1 and CXCL2 in the plasma, desensitization of CXCR2,
and impaired formation of chemokine gradients for neutrophil
influx to the lung. In normal mice, CXCL5 was found bound to
circulating erythrocytes, and abundant preformed CXCL5 was
found in platelets, which are the source of homeostatic CXCL5
loaded onto DARC. In contrast to homeostatic conditions, resi-
dent cells are responsible for CXCL5 generation in the lung
and most of the increased CXCL5 in the blood during E. coli
pneumonia. In a milder and self-limited inflammatory model, on
the other hand, CXCL5 appeared to be the dominant effector
of neutrophil influx to the lung, due, at least in part, to prolonged
expression (compared to CXCL1 and CXCL2) in the lung.
In summary, these results provide the first evidence that the
chemokine scavenging function of erythrocyte DARC is inhibited
by homeostatic and inflammatory CXCL5 in vivo during inflam-
mation. These data further indicate that CXCL5, through its inter-
action with erythrocyte DARC, regulates the availability of
binding sites for other ELR+ CXC chemokines released during
inflammation. While established during normal homeostasis,
these effects are only observed in severe inflammatory disease.
In addition to its role in chemokine scavenging, CXCL5 also plays
a critical direct role in pulmonary inflammatory responses in
a self-limited LPS inhalation model. As an example of a chemo-
kine with both homeostatic and inflammatory functions, CXCL5
occupies a unique niche within the family.
RESULTS
CXCL5 Regulates Neutrophil Homeostasis in Bone
Marrow
To explore the role of CXCL5 in lung inflammation in vivo, we
generated CXCL5-deficient mice with the strategy of deleting
all Cxcl5 coding regions (Figure S1). CXCL5-deficient mice
were viable and fertile without any abnormalities in their general
appearance. Histology of a survey of organs was normal (data
not shown). In bone marrow (BM), the total numbers and
percentages of Gr-1+ cells and relatively mature Gr-1+CXCR2+
cells in Cxcl5/mice were higher than that of WT mice (Figures
S2E and S2F), indicating that CXCL5 plays a role in neutrophilhomeostasis, whereas the numbers and percentages of blood
neutrophils (Figures S2G and S2H) and the parameters of the
other hematopoietic lineages (data not shown) between WT
and Cxcl5/ mice are similar.
CXCL5 Inhibits Neutrophil Influx to the Lung
during E. coli Pneumonia
In order to determine the consequences of CXCL5 deficiency on
host responses, we used a mouse model of E. coli pneumonia.
Intratracheal (i.t.) challenge of mice with 107 CFU E. coli induces
a severe lung infection with bacterial replication and a high
mortality. Neutrophil influx to the lung in Cxcl5/ mice was
potentiated 8 and 24 hr after infection, and lung myeloperoxi-
dase (MPO) activity similarly increased as compared to WT
mice (Figures 1A–1C). Thus, despite its recognized function as
a neutrophil chemoattractant, CXCL5 inhibited neutrophil influx
in this severe inflammatory setting. Consistently, Cxcl5/ mice
showed fewer bacteria in the lung compared to WT mice
(Figure 1D). The mortality of Cxcl5/ mice within 24 hr after
E. coli challenge was lower than that of WT mice, and the lung
wet-to-dry ratio at 24 hr, which indicates the severity of edema,
was attenuated in Cxcl5/ mice (Figures 1E–1F), indicating
that CXCL5 aggravates acute lung injury during severe E. coli
pneumonia. Histology of the lungs (Figure 1L) and cytospin of
bronchoalveolar lavage fluid (BALF) (Figure S3) at 24 hr after
challenge showed more inflammatory cells and fewer E. coli in
the lungs of Cxcl5/ mice as compared to WT mice. The
amounts of CXCL1, CXCL2, TNF-a, and IL-6 in the BALF upon
E. coli challenge were not affected by CXCL5 deficiency except
that the amounts of CXCL2 at 24 hr and IL-6 at 8 hr in the BALF
of Cxcl5/ mice were attenuated relative to WT mice (Fig-
ures 1G–1K). These results indicate that CXCL5 deficiency
increased neutrophil influx, accelerated bacteria clearance,
improved pulmonary edema, and protected mice from severe
E. coli pneumonia. In WT mice, the amounts of CXCL1 and
CXCL2 in the BALF were much larger than that of CXCL5
(Figure 1G–1I), suggesting that CXCL1 and CXCL2 may be the
predominant chemoattractants in mediating neutrophil influx to
the lung upon E. coli challenge.
In order to determine mechanisms by which neutrophil accu-
mulation was impaired in the presence of CXCL5, expression
of CXCR2, the receptor for the ELR+CXC chemokines was quan-
tified. Surface expression of CXCR2 on neutrophils in the BM
and blood was dramatically downregulated after E. coli chal-
lenge in WT mice, less downregulated in Cxcl5/ mice, and
unaffected in either group after LPS inhalation (Figure S4). Since
high concentrations of CXCR2 ligands induce desensitization of
the receptor, manifest in attenuated surface CXCR2 (Prado et al.,
1996; Sabroe et al., 1997;Wiekowski et al., 2001), the downregu-
lation of CXCR2 on Gr-1+ cells suggested that E. coli challenge
might induce large amounts of ELR+ CXC chemokines in blood.
Furthermore, these data suggest higher concentrations of
CXCR2 ligands in the plasma of WT mice than that of Cxcl5/
mice, given greater downregulation of surface CXCR2 expres-
sion on blood neutrophils of the former.
In exploring this possibility, we found that E. coli exposure
induced high-level expression of plasma CXCL1 and CXCL2 in
WT mice, which was dramatically attenuated in Cxcl5/ mice
(Figures 2B and 2C), indicating that CXCL5 regulates plasmaImmunity 33, 106–117, July 23, 2010 ª2010 Elsevier Inc. 107
Figure 1. The Pulmonary Immune Responses, Lung Injury and Host Defense upon E. coli Intratracheal Challenge
White blood cells (A) and neutrophils (B) were counted in the BALF of WT and Cxcl5/ mice (n R 5 mice/group) at 8 and 24 hr point after 107 CFU E. coli
intratracheal (i.t.) inoculation. The lung myeloperoxidase activities (C) were measured from lung homogenate. The lung bacterial burden (D) was measured in
the lung homogenate by serial dilution on MacConkey plates. The mortality rate of mice (E) was monitored within 24 hr after inoculation, and the fractions above
the columns represent the number of dead mice among the number of mice inoculated. The lung wet/dry ratios (F) were measured after drying the whole lung in
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Figure 2. Plasma Chemokines, Chemokine
Gradients, and CXCR2 Desensitization
upon E. coli Challenge
WT and Cxcl5/ mice (n = 4 mice/group) were i.t.
inoculated with 107 CFU E. coli, at different time
points, and the blood was drawn from vena cava
after injection of 3.2% sodium citrate. The plasma
amounts of CXCL5, CXCL1, and CXCL2 were
measured upon E. coli challenge (A–C) by ELISA.
The ratio of BALF to plasma CXCL1 (D) and
CXCL2 (E) were calculated with the mean value of
chemokine concentrations from Figures 1G and
1H and Figures 2B and 2C. The gating of Gr-1+
cell in the BM (F) and the representative calcium
responses (G) of BM Gr-1+ cells of naive WT mice
(red line), E. coli-challenged (24 hr after challenge)
WT (blue line) and Cxcl5/ mice (green line)
(n = 3 mice/group) to 10 nM CXCL1 are shown.
The BM cells were stained with APC-conjugated
Gr-1 antibody and labeled with indo-1 AM. Data
are representative of two independent experi-
ments. N.D., not detected. **p < 0.01; ***p < 0.001.
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CXCL5 in Chemokine Scavenging and Lung InfectionCXCL1 and CXCL2 concentrations in this model of severe E. coli
pneumonia. The relative ratio of local to plasma chemokine
concentrations reflects the relative values of gradients that regu-
late neutrophil influx to tissues (Blackwell et al., 1999; Call et al.,
2001), even though the absolute value of individual chemokines
is affected by dilution of BALF during preparation. Measurement
of these parameters indicated that Cxcl5/ mice better
preserved chemokine gradients for CXCL1 and CXCL2 from
the blood to alveolar space upon E. coli challenge as compared
to WTmice (Figures 2D and 2E), due, in large part, to the plasma
concentrations of CXCL1 and CXCL2. As a possible reflection of
ligand-induced desensitization, bone-marrow-derived neutro-
phils of WT mice at 24 hr after E. coli challenge are unresponsive
to 10 nM CXCL1 stimulation in vitro (the ratio of indo-1[violet]/
[blue] peaked at 365 ± 34), while the neutrophils of Cxcl5/
mice still retain responsiveness (the ratio of indo-1[violet]/[blue]
peaked at 541 ± 27), albeit attenuated (Figures 2F and 2G), sug-
gesting that CXCR2 desensitization by CXCR2 ligands in WT
blood leads to a greater impairment of neutrophil chemotaxis
to the lung and presumably, neutrophil mobilization from bone
marrow. Thus, CXCL5 inhibited neutrophil influx to the lung, at
least in part, by contributing to elevated plasma concentrations
of CXCL1 and CXCL2, leading to attenuation of chemokine80Coven for 48 hr. (nR 5mice/group). Concentrations of CXCL1 (G), CXCL2 (H), CXCL5 (I), TNF-a (J), and IL
micewere i.t. challenged with sterile saline. Data are representative of two independent experiments. Represe
samples at 24 hr of WT and Cxcl5/ mice (n = 4 mice/group) is shown. The lungs were fixed with 10% neu
40 mm. N.D., not detected. *p < 0.05; **p < 0.01 ; ***p < 0.001.
Immunity 33, 106–gradients and CXCR2 desensitization in
a model of severe E. coli pneumonia.
CXCL5 Inhibits Chemokine
Scavenging in Blood in Part through
Binding to Erythrocyte DARC
Having detected markedly decreased
CXC chemokines in blood of Cxcl5/
mice, we hypothesized that the interactionof CXCL5 with erythrocyte DARC alters the disposition of CXCL1
andCXCL2expressed during inflammatory events and increases
their plasma concentrations. In order to test this, we designed
a simple in vitro chemokine scavenging assay and compared
the plasma concentrations of CXCL1, CXCL2, and CXCL5
after addition of exogenous chemokines to whole blood from
WTandCxcl5/mice. As seen in Figures 3A–3C, in vitro incuba-
tion of whole blood with CXCL1, CXCL2, or CXCL5 resulted
in significantly lower concentrations in plasma of Cxcl5/
mice as compared to WT mice, indicating that endogenous
amounts of CXCL5, even under homeostatic conditions, regulate
plasma concentrations of competitor chemokines CXCL1 and
CXCL2. Consistent with these in vitro findings, the plasma
concentrations of CXCL5, CXCL1, and CXCL2 in Cxcl5/ mice
were attenuated relative to those in WT mice after intravenous
injection of recombinant CXCL5, CXCL1, and CXCL2 (Figures
3D–3F). Notably, CXCL2 in blood was cleared in blood with an
extraordinary rate. Even at 30 min after i.v. injection, most
CXCL2 disappeared from the plasma, probably because of its
DARC-independent loss to distal organ or tissues (Fukuma
et al., 2003).
To determine whether erythrocyte DARC is directly respon-
sible for clearance of CXCL1 or CXCL2 from blood, as suggested-6 (K) in the BALFweremeasured by ELISA. Control
ntative hematoxylin & eosin staining (L) of fixed lung
tral formalin. Arrows indicate E. coli rods. Size bar,
117, July 23, 2010 ª2010 Elsevier Inc. 109
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Figure 3. CXCL5 Inhibits Chemokine
Scavenging in Whole Blood In Vitro and
In Vivo
The plasma concentrations of CXCL1 (A), CXCL2
(B), and CXCL5 (C) were measured by ELISA after
incubation of the citrated blood from WT and
Cxcl5/mice (n = 3mice/group) with recombinant
CXCL1, CXCL2, and CXCL5, respectively, for
15 min. The plasma concentrations of CXCL1 (D),
CXCL2 (E), and CXCL5 (F) in the plasma of WT
and Cxcl5/ mice were measured at different
time points after intravenous injection of recombi-
nant CXCL1, CXCL2, and CXCL5, respectively.
Data are representative of two independent
experiments. N.D., not detected. *p < 0.05;
***p < 0.001.
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CXCL5 in Chemokine Scavenging and Lung Infectionby a recent study (Reutershan et al., 2009), we measured the
scavenging capability of Darc/ versus WT blood. The scav-
enging capacities ofDarc/whole citrated blood for exogenous
CXCL1 and CXCL5 were much attenuated as compared to that
of WT mice (Figures 4A and 4B). In addition, Darc/ red cells
did not bind CXCL5 (Figure 4G) or CXCL2 (Mangalmurti et al.,
2009). Collectively, these results indicate that erythrocyte
DARC is largely responsible for scavenging CXCL1, CXCL2,
and CXCL5 in murine whole blood in vitro, and WT blood still
retains significant chemokine scavenging capacities, even
though a considerable amount of homeostatic CXCL5 binds to
erythrocyte DARC (Figure 4C). CXCL5-regulated chemokine
scavenging (Figures 3A–3F) may also be attributed to endothelial
DARC, and other chemokine scavenging molecules, such as
heparan sulfate proteoglycans (HSPGs), in addition to erythro-
cyte DARC.
In order to determine how chemokines partition between
plasma and erythrocytes, we measured plasma and erythro-
cyte-associated CXCL5 in blood of naive WT mice. As seen in
Figure 4C, we found large amounts of CXCL5 in association
with erythrocyte DARC rather than plasma, while under homeo-
static state, CXCL1 and CXCL2 were not found in either plasma
or erythrocyte compartments. To model increases in CXCL1, we
injected recombinant murine CXCL1 intravenously into both WT
and Cxcl5/ recipients. The increased chemokine scavenging
for exogenous CXCL1 in Cxcl5/ blood as compared to WT
blood (see also Figure 3D) were found to be at least partially
due to increased erythrocyte associationwithCXCL1 (Figure 4D).
These findings are the first, we believe, to demonstrate that
erythrocyte DARC binds a chemokine (CXCL5) under homeo-
static conditions and in so doing, impairs chemokine scavenging
in blood.
To further elucidate the mechanisms whereby the binding of
CXCL5 with erythrocyte DARC regulates the availability of
CXCL1 and CXCL2 in blood during E. coli pneumonia, we com-
pared the binding affinities of murine ELR+ CXC chemokines to
erythrocyte DARC. In radioligand binding assays, the ability of
CXC chemokines to compete with 125I-Gro-a (human CXCL1)
on purified murine erythrocytes was compared in a system
dependent upon DARC (Figure 4G). The relative binding activity
of murine CXC chemokines is as follows: CXCL5 70 amino acids
(aa). CXCL5 (most potent short form)/ CXCL2/ CXCL1/110 Immunity 33, 106–117, July 23, 2010 ª2010 Elsevier Inc.CXCL5 93 aa (Figures 4E and 4F, p < 0.05). Note that the
N-terminal cleavage of the chemokine CXCL5 (from the mature
CXCL5 93 aa to the 70 aa form) significantly enhanced its binding
affinity to erythrocyte DARC. The Ki (equilibrium dissociation
constant) for various ELR+ CXC chemokines showed similar
relative binding affinities for erythrocyte DARC even when a
CC chemokine, 125I-hCCL2, was used as the radioligand (Fig-
ures 4G and 4H). Thus, CXCL5-70 demonstrates the highest
binding affinity for erythrocyte DARC than either CXCL1 or
CXCL2, but all of them demonstrated high-affinity binding.
Although the exact cleaved forms of CXCL5 binding with eryth-
rocyte DARC under homeostatic and inflammatory state is not
clear, this result suggests that CXCL5-70 may preferentially
bind erythrocyte DARC as compared to CXCL1 and CXCL2
during inflammation, which might impair their scavenging.
Finally, when plasma- and erythrocyte-associated chemokines
were measured in response to E. coli pneumonia, much greater
percentages of CXCL1 remained bound to erythrocyte DARC in
the blood of CXCL5/ mice relative to WT mice (Figure 4I).
These data further support the concept that CXCL5 inhibition
of erythrocyte DARC chemokine scavenging increases the
plasma concentration of CXCL1 and CXCL2 in a severe E. coli
pneumonia model.
Consistent with the notion that DARC is already substantially
occupied in basal conditions, we also showed that Darc/
mice exhibited comparable neutrophil influx to the lung and
plasma CXCL1 level to WT mice (Figures S5A–S5D). These
data at least partially explain why the erythrocyte DARC ‘‘chemo-
kine sink’’ hypothesis has been difficult to prove, as DARC
binding sites do not appear to be readily available in the WT
controls during inflammation. To further investigate whether
DARC is completely responsible for CXCL5-regulated chemo-
kine scavenging, we found that with newly generated Darc/:
Cxcl5/ double knockout mice, CXCL5-regulated chemokine
scavenging in vitro is not totally dependent on DARC (Fig-
ure S5E), suggesting that other chemokine scavenging mole-
cules than DARC still contribute to CXCL5-regulated chemokine
scavenging. We further found that CXCL5 was mobilized in the
plasma of heparin-treated blood compared to PBS-treated
blood both in vivo and in vitro (Figure S8F), suggesting that
heparin binding might liberate CXCL5 from other molecules.
Since heparan sulfate proteoglycans (HSPGs) are expressed
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Figure 4. CXCL5 Regulates Plasma Chemokines at
Least in Part through Homeostatic and High-
Affinity Binding with Erythrocyte DARC
The plasma concentrations of CXCL5 (A) and CXCL1 (B)
were measured by ELISA after incubation of the citrated
blood from WT and Darc/ mice (n = 4 mice/group) with
recombinant CXCL5 or CXCL1, respectively, for 15 min.
The amounts of plasma and erythrocyte DARC-binding
CXCL1, CXCL2, and CXCL5 in blood of naive WT mice
(n = 3 mice/group) were measured by ELISA (C). The
amounts of plasma CXCL1 and erythrocyte DARC-binding
CXCL1 were also measured by ELISA from the citrated
blood 15 min after intravenous injection of 1 mg recombi-
nant CXCL1 into WT and Cxcl5/mice (n = 3 mice/group)
(D). Competitive binding assay using 125I-hGro-a (CXCL1)
(E) or 125I-hCCL2 (G) for purified murine erythrocytes
from WT (E and G) and Darc/ (G), CXCL5-70 Darc/
mice with various concentrations of cold ligands CXCL5-
70, CXCL1, CXCL2, CXCL5-93, and unlabeled hGro-a
(CXCL1) or hCCL2 were performed. The Ki (equilibrium
dissociation constant) values (F), (H) for cold competitors
(n = 4 times), were calculated and show distinct binding
affinities for red cell DARC within the ELR+ CXC chemo-
kines family (p < 0.05 for all ligands comparisons).
Darc/ red cells do not bind appreciably radiolabeled
ligands (G). The percentages of erythrocyte DARC-binding
CXCL1 in blood (I) were calculated after measurement of
plasma and erythrocyte DARC-binding CXCL1 in blood
of WT and Cxcl5/ mice (n = 3 mice/group) at different
time points upon 107 CFU E. coli i.t. challenge. N.D., not
detected. *p < 0.05; **p < 0.01; ***p < 0.001.
Immunity
CXCL5 in Chemokine Scavenging and Lung Infectionon almost all cell types (Dreyfuss et al., 2009), HSPGs may also
mediate CXCL5-regulated chemokine scavenging.
Preformed CXCL5 in Platelets Contributes
to the Homeostatic CXCL5 in Blood
The sources of circulating chemokines in the mouse are not well
understood. While considering the possibility that circulating
platelets are a source, we found large amounts of CXCL5
(Figure 5A), little CXCL1 (Figure 5B), and no CXCL2 or CXCL15
(data not shown) in the plasma after traditional retro-orbital
bleeding (even into EDTA-coated tubes) from naive WT mice,
while no chemokines were detected using similar methods in
naive Cxcl5/ mice. Accordingly, since this traditional bleeding
method does not prevent coagulation or prevent platelet release
reactions, we prepared plasma without coagulation using bloodImmunity 33withdrawal with sodium citrate (coagulation-
negative bleeding) (Sommeijer et al., 2005),
and found much lower concentrations of
CXCL5 in plasma from coagulation-negative
bleeding than in traditional bleeding
(Figure 5A). These data suggest that activated
platelets secrete CXCL5 into plasma during
even the modest coagulation that accompanies
traditional bleeding methods. As a partial confir-
mation of this hypothesis, isolated platelets from
WT and Cxcl5/ mice were stimulated with
thrombin or were snap-frozen and thawed
twice, or directly lysed, and the presence of che-
mokines was determined using immunoblotanalysis. As seen in Figures 5C and 5D, large amounts of
CXCL5 (mostly the least active CXCL5-93 form, both in lysates
and supernatant after platelet chemokine release), but not
CXCL1, was detected in the platelets. Likewise, our results
also suggest that activated platelets secrete little CXCL1 into
plasma during coagulation (Figure 5B), nor could immunoblot
analysis and ELISA detect the presence of CXCL1 in platelets
and the coagulation-negative plasma (Figures 2B and 6K) of
naive mice. In conclusion, among these four ELR+ CXC chemo-
kines, only preformed CXCL5 is abundant in murine platelets.
In order todeterminewhetherplatelets are the sourceof homeo-
static CXCL5 in naive WT mice, we first determined whether it
was derived from the hematopoietic compartment. Reconstitution
of WT and Cxcl5/ mice with Cxcl5/ and WT marrow demon-
strated that those mice with Cxcl5/ marrow lacked both, 106–117, July 23, 2010 ª2010 Elsevier Inc. 111
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Figure 5. Large Amounts of Preformed
CXCL5 in Platelets and Platelet Origin for
Homeostatic CXCL5 in Blood
Comparison of plasma concentrations of CXCL5
(A) by retro-orbital bleeding (with coagulation)
and vena cava bleeding (by injection of sodium
citrate, without coagulation) in WT mice (n =
4 mice/group) upon 107 CFU E. coli i.t. challenge,
measured by ELISA. The plasma concentration
of CXCL1 (B) by retro-orbital bleeding from naive
WT mice and Cxcl5/ mice (n = 4 mice/group)
were measured by ELISA. CXCL5, but not
CXCL1, is detected in inactivated platelets of naive
WT mice by western blot (C), and both preformed
and secreted CXCL5 by thrombin stimulation from
platelet is mostly CXCL5-93 form (D). R, recombi-
nant CXCL5-93 (9.8 kD) and CXCL5-70 (7.6 kD);
Fr/th, the supernatant after separated platelets
were snap-frozen and thawed twice; thrombin,
the supernatant after separated WT platelets
were stimulated with 1 U/ml thrombin for 10 min
at 37C; WT or Mu, lysate of inactivated platelets
in WT or mutant Cxcl5/ mice. WT and Cxcl5/
mice were reconstituted with BM from WT and
Cxcl5/ mice, respectively, after 8 weeks, and
the citrated blood will be prepared from the mice
in each group (n = 4 mice/group). The plasma
and red cells were separated, then the plasma
CXCL5 concentrations (E) and erythrocyte-binding
CXCL5 (F) were measured by ELISA. After incuba-
tion of the citrated blood with recombinant CXCL5
for 15 min, the plasma concentrations of CXCL5
(G) were measured. WW, BM from WT donor
mice into WT recipient mice; WK, BM from WT
donor mice into Cxcl5/ recipient mice; KW, BM
from Cxcl5/ donor mice into WT recipient
mice; KK, BM from Cxcl5/ donor mice into
Cxcl5/ recipient mice. The amounts of plasma
CXCL5 and erythrocyte-binding CXCL5 in citrated
blood of Mpl/ mice (H), Fog-1ki/ki mice (I), and
their respective WT control mice were mea-
sured by ELISA. The plasma concentrations of
CXCL4 and CXCL7 were measured in the citrated
blood of Mpl/ mice (K), Fog-1ki/ki mice (L),
and their respective WT control mice as well.
Only the CXCL7-74 (b-thromboglobulin) form is
detected in platelets by immunoblot (J). R,
recombinant CXCL7-74 aa (8.2 kD). Data are
representative of two independent experiments.
N.D., not detected. *p < 0.05; **p < 0.01;
***p < 0.001.
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CXCL5 in Chemokine Scavenging and Lung Infectionplasma- and erythrocyte-bound CXCL5 (Figures 5E and 5F). In
contrast, mice receiving WT marrow demonstrated both plasma
and erythrocyte-bound CXCL5, and decreased scavenging of
chemokines was found in blood from those mice (Figure 5G).
In order to confirm more specifically the platelet origin of
homeostatic CXCL5 in blood, we adopted a genetic approach
using two thrombocytopenic Mpl/ and recently described
Fog-1 ki/ki mouse models (Alexander et al., 1996; Miccio et al.,
2010). In both models, defective thrombocytopoiesis is associ-
ated with markedly reduced numbers of circulating platelets
(but other lineages are intact) and is associated with markedly
decreased amounts of plasma- and erythrocyte-binding
CXCL5 as compared to WT mice (Figures 5H and 5I). CXCL7112 Immunity 33, 106–117, July 23, 2010 ª2010 Elsevier Inc.(b-thromboglobulin form, shown in Figure 5J) and CXCL4 are
the two most abundant chemokines in the a-granule of platelets
together with CXCL5, and their plasma concentrations were
also greatly attenuated in Mpl/ and Fog-1ki/ki mice compared
to that in WT mice (Figures 5K and 5L), indicating that platelets
are the origin of homeostatic CXCL5 in blood and further sug-
gesting that CXCL4, -5, and -7 are coregulated at the homeo-
static level of platelet release.
CXCL5 Predominates in Mediating Neutrophil Influx
to the Lung upon Nebulized LPS Stimulation
In order to determine whether CXCL5 regulates neutrophil influx
as seen in murine E. coli pneumonia under less extreme
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Figure 6. CXCL5 Is Required for Pulmonary Immune Responses to LPS Inhalation
WT and Cxcl5/ mice (n = 3 mice/group) were exposed to nebulized LPS (0.3 mg/ml) for 30 min, at different time points, and white blood cells (WBC) (A) and
neutrophils (B) were counted in the BALF. The lung MPO activities (C) were measured from lung homogenate. The protein amounts of TNF-a (D), IL-6 (E), CXCL5
(F), CXCL1 (G), CXCL2 (H), and CXCL15 (I) in the BALF were measured by ELISA. At 4 and 24 hr after LPS inhalation, the blood was drawn from inferior vena cava
after injection of 3.2% sodium citrate, and the plasma concentrations of CXCL5 (J) and CXCL1 (K) were measured by ELISA. Data are representative of two inde-
pendent experiments. N.D., not detected. *p < 0.05; **p < 0.01; ***p < 0.001.
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CXCL5 in Chemokine Scavenging and Lung Infectionconditions, we used a model of self-limited inflammation
induced by inhaled LPS (Jeyaseelan et al., 2004). In contrast to
the E. coli pneumonia model, neutrophil influx to the lung in
response to LPS inhalation was dramatically attenuated in
Cxcl5/ mice versus WT mice (Figures 6A and 6B). However,
the lung myeloperoxidase (MPO) activities after lavage and
perfusion were comparable between WT and Cxcl5/ mice
(Figure 6C), indicating that the migration of neutrophils into the
alveolar space, but not other lung compartments, is facilitated
by the presence of CXCL5. At 4 hr after LPS inhalation, the
amounts of TNF-a and IL-6 in the BALF were attenuated in
Cxcl5/ mice as compared to WT mice (Figures 6D and 6E),
but the expression of CXCL1 and CXCL2 in the BALF was not
affected by CXCL5 deficiency (Figures 6G and 6H). Furthermore,
CXCL15 expression in the BALF was attenuated only at 24 hr in
Cxcl5/mice versus WTmice (Figure 6I). These results indicatethat CXCL5 plays a dominant role in regulating pulmonary
inflammatory responses to inhaled LPS, perhaps because of
its prolonged expression pattern. CXCL1 and CXCL2 peaked
at 2 and 4 hr, while CXCL5 expression was more prolonged,
reaching its peak at 8 hr with a considerable amount remaining
in the BALF at 24 hr (Figures 6F–6H). We further measured the
concentrations of these chemokines in circulation. Unlike
CXCL1 (Figure 6K), CXCL2, and CXCL15 that are undetectable
in blood (data not shown), CXCL5was detectable at low concen-
trations in plasma of untreated WT mice (Figure 5J). LPS inhala-
tion does not stimulate expression of CXCL2, CXCL5, and
CXCL15 in plasma and only induced a low-level expression of
CXCL1 in the plasma of WT mice, which was attenuated in
Cxcl5/ mice, suggesting that this is also a consequence of
improved chemokine scavenging by Cxcl5/ mice. These
results indicate that LPS inhalation induces a local inflammatoryImmunity 33, 106–117, July 23, 2010 ª2010 Elsevier Inc. 113
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Figure 7. The Origin of CXCL5 in Both LPS Inhalation and Severe E. coli Pneumonia Model
WTandCxcl5/micewere reconstitutedwith BM fromWTandCxcl5/mice respectively, after 8 weeks, and the chimeric micewere exposed to 0.3mg/ml LPS
for 30 min (A) or intratracheally challenged with 107 CFU E. coli (n = 3 mice/group) (B and C). At 8 hr after challenge, the BALF (A and B) and plasma samples (C)
were prepared and CXCL5 measured by ELISA. WW, BM fromWT donor mice into WT recipient mice; WK, BM fromWT donor mice into Cxcl5/ recipient mice;
KW, BM from Cxcl5/ donor mice into WT recipient mice; KK, BM from Cxcl5/ donor mice into Cxcl5/ recipient mice. Data are representative of two
independent experiments. N.D., not detected.
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CXCL5 in Chemokine Scavenging and Lung Infectionstate, and CXCL5 dominates in mediating neutrophil influx to the
lung airspace due, at least in part, to its more prolonged expres-
sion than CXCL1 and CXCL2 in the lung.
The data presented so far highlight two different roles of
CXCL5, exemplified in a local, self-limited inflammatory re-
sponse contrasted to a severe, lethal response with high
concentrations of circulating chemokines. In order to determine
whether these dichotomous (mild and severe) lung inflammation
models represent opposite ends of a spectrum or completely
distinct events, we used a high-dose LPS inhalation model, the
intensity of which is intermediate between the LPS or E. coli
models. Interestingly, initial neutrophil influx to the lung is
enhanced in Cxcl5/ mice, while CXCL1 plasma levels were
attenuated. At later time points (Figure S6), neutrophil numbers
decreased more rapidly than in WT. These data imply the rele-
vance of CXCL5 not only to initiation of inflammation, but also
to resolution of inflammation. In addition, we also used a low-
dose 106 CFU E. coli pneumonia model, which showed com-
parable severity of inflammation to the high-dose LPS inhalation
model (as judged by comparable CXCL1 plasma amounts). At 8
hr, neutrophil influx to the lung was increased inCxcl5/mice at
least in part because of increased chemokine scavenging in
blood, which led to a decrease in lung bacterial burden at
24 hr (Figure S7). These two new models, demonstrating similar
phenotypes at early time points, suggest that the impact of
CXCL5-regulated chemokine scavenging on pulmonary inflam-
matory responses is not because of the difference of compli-
cated E. coli versus simple LPS challenge, but mostly because
of the differential amounts of ELR+ CXC chemokines in plasma
between two genotypes.
Resident Cells Are the Source of Pulmonary CXCL5
and Most Plasma CXCL5 during E. coli Pneumonia
Wehave previously shown that CXCL5 is expressed by AE II cells
in response to LPS stimulation in vivo, and AE II cells, but not
neutrophils and alveolar macrophages, express CXCL5 after
LPS stimulation in vitro (Jeyaseelan et al., 2005a). Because these
studies could not rule out the possibility that another hematopoi-
etic cell might still provide the majority of CXCL5, we used BM
chimeric mice to test the importance of lung resident cells. As
seen in Figure 7, only WT recipient mice (whatever the donor114 Immunity 33, 106–117, July 23, 2010 ª2010 Elsevier Inc.genotype) were able to express CXCL5 in the lung in either
LPS- or E. coli-induced lung inflammation (Figures 7A and 7B).
These data demonstrated that lung resident cells are the source
of lung CXCL5 during lung inflammation. Surprisingly, we found
that resident cells also contributed about two-thirds of plasma
CXCL5, while hematopoietic cells contributed about one-third
(Figure 7C). Considering that baseline CXCL5 (the majority
bound to erythrocytes) in blood was contributed by platelets,
these data demonstrate that resident cells are the major source
of inflammatory plasma CXCL5 in this severe E. coli pneumonia
model and, hence, that lung epithelial cells regulate pulmonary
inflammatory responses through inhibition of chemokine
scavenging after E. coli challenge.
DISCUSSION
Pneumonia from gram-negative bacteria is a leading cause of
mortality from infectious diseases in the U.S. (Armstrong et al.,
1999; Mizgerd, 2006). Neutrophil influx is a crucial component
of innate immunity against bacterial infection, but excess neutro-
phil influx and activation may initiate acute lung injury, necessi-
tating exquisite control over inflammatory cell recruitment and
activation. One of the components of this regulatory system is
the family of ELR+ CXC chemokines (CXCL1, -2, -5, and -15),
which play critical roles in the inflammatory responses in rodents
and humans. Despite considerable homology between these
family members, it is unclear whether they are functionally
redundant or capable of distinct actions. In humans, CXCL5
was found to be most strongly and consistently correlated with
neutrophil numbers in the lung fluids of patients with acute
respiratory distress syndrome (ARDS) (Goodman et al., 1996),
highlighting the potential importance of CXCL5 in regulation of
lung inflammation and injury.
In attempting to define genetically the role of CXCL5 in pulmo-
nary inflammation and host defense against gram-negative
bacterial pneumonia, we have uncovered unique aspects of
CXCL5 biology. With in vitro and in vivo studies, we have demon-
strated that CXCL5 inhibits chemokine scavenging at least in
part through its homeostatic and high-affinity binding with
erythrocyte DARC. Hence, in the absence of CXCL5, DARC
scavenges proinflammatory chemokines, thus contributing to
Immunity
CXCL5 in Chemokine Scavenging and Lung Infectionreshaping the chemokine gradients for neutrophil influx to the
lung during severe E. coli pneumonia. In contrast, in response
to LPS inhalation, a self-limited inflammatory response in the
lung, deletion of CXCL5 markedly impairs neutrophil accumula-
tion in the airspace, thus revealing critical nonredundant roles for
this chemokine in lung inflammation in these two models.
Furthermore, CXCL5 demonstrates features of both homeostatic
chemokines (detected in plasma and bound to erythrocytes of
normal mice) and inflammatory chemokines (enhanced expres-
sion during inflammation). Perhaps most surprising of all, our
data indicate that the source of circulating CXCL5 in the basal
homeostatic condition is the platelet, while lung resident cells
(principally AE II cells, we suggest) are the source of CXCL5 in
the lung and (to a large extent) blood during lung inflammation.
Based on our observations, we propose a model in which
during homeostatic conditions, platelet-derived CXCL5 is
loaded onto erythrocyte DARC. During self-limited inflammation,
CXCL5 itself, perhaps by virtue of its prolonged expression by
AE II cells in the lung, is necessary for optimal neutrophil
accumulation. CXCL5 in this scenario has little effect on local
concentrations of CXCL1 or -2, which are only transiently (albeit
significantly) induced and are but minimally detected in plasma.
During a severe inflammatory response, such as that accompa-
nying E. coli pneumonia, further expression of CXCL5 by AE II
cells inhibits the chemokine scavenging capability of DARC, at
a time when the production of CXCL1 and CXCL2 increases
dramatically, resulting in marked increases in circulating plasma
concentrations of these chemokines, with adverse conse-
quences for the efficient accumulation of neutrophils. Our
studies support the ‘‘chemokine sink’’ function of erythrocyte
DARC, while suggesting that, under normal circumstances, it is
inhibited by endogenous CXCL5 from platelets and further
impaired by AE II cell-derived CXCL5 during severe E. coli
pneumonia. The phenotypes of WT mice we observed in this
severe E. coli pneumonia model resemble that of ‘‘cytokine
storm (hypercytokinemia)’’ in influenza pneumonia. Deletion of
CXCL5 in our model decreased large circulating amounts of
chemokines CXCL1 and -2 and improved survival by permitting
effective neutrophil accumulation and bacterial killing.
DARC has previously been reported to bind many proinflam-
matory chemokines, but not homeostatic chemokines (Allen
et al., 2007; Borroni et al., 2008; Gardner et al., 2004). Here,
we have demonstrated that CXCL5 is also a homeostatic che-
mokine, derived from platelets, which modulates neutrophil
homeostasis in naive mice. Thus, the binding of homeostatic
chemokines to DARC, and the attendant consequences, are
findings of this work that may alter our view of DARC function.
Our analysis, however, has focused on erythrocyte DARC-
binding chemokines and functioning as sink (and reservoir).
DARC is also expressed on endothelial cells, where it exerts
additional actions that promote migration. Whether endothelial
DARC contributes to the scavenging functions described here
will require further investigation.
As befits a chemokine with homeostatic functions, CXCL5 is
found circulating in normal mice, almost all of it bound to erythro-
cytes. Our studies demonstrated this circulating CXCL5 is
derived from platelets. Given the potential role of platelets in a
variety of inflammatory diseases (Gear and Camerini, 2003),
such as atherosclerosis and acute lung injury (Bozza et al.,2009), it is tempting to speculate that platelet-derived CXCL5
maybe involved in establishingconditions that alter a subsequent
inflammatory response. Indeed, we have demonstrated that
the homeostatic platelet-derived CXCL5 significantly inhibits
chemokine scavenging both in vitro and in vivo. In striking
contrast, however, lung cells, but not platelets, provided most
of the inflammation-induced increases in CXCL5 and the atten-
dant inhibition of chemokine scavenging after E. coli challenge.
Furthermore, most CXCL5 in platelets or secreted from them
after thrombin stimulation are the less active CXCL5-93 form.
Previous studies have indicated that many cellular forms of
CXCL5 can be detected, including the most potent CXCL5-70
and less potent CXCL5-93 in response to stimulation (Wuyts
et al., 1999). Our analysis showed many forms released from
platelets, but most was CXCL5-93. Whether platelet-secreted
CXCL5-93 canbecleaved intopotentCXCL5-70bymatrixmetal-
loproteinases during inflammation (Tester et al., 2007), and what
forms of CXCL5 are released by AE II cells, or detected in plasma
or bound to erythrocytes in both homeostatic and inflammatory
conditions, are the subject of on-going study. Platelets also
contain CXCL7 (b-thromboglobulin), another ELR+ CXC chemo-
kine in mice, but it has not yet been determined whether murine
CXCL7 is processed toaneutrophil-chemoattractant formsimilar
to human NAP-2(Smith et al., 2002).
While increases in circulating CXCL1 and -2 appear to be a
consequence of impaired scavenging, the mechanism by which
elevation of circulating plasma chemokines attenuates neutro-
phil accumulation to the lung and other organs remains obscure.
Here, we propose two mechanisms. First, we suggest that the
chemokine gradients (the relative ratio of BALF versus plasma
concentrations of CXCL1 and CXCL2) are important, especially
considered in light of the dilution consequent to lavage, but
we also suggest that the absolute value of the plasma chemo-
kines may also be relevant. Ligand-induced desensitization of
CXCR2, the receptor for CXCL1, -2, -5 and -15, occurs normally
during chemotaxis in vitro and migration in vivo and is thus
a physiologic process. Here, we have documented desensitiza-
tion of neutrophils even before their entry into the circulation
in WT mice after E. coli exposure. Isolation of BM-derived
neutrophils demonstrated loss of surface CXCR2 and nonres-
ponsiveness to CXCL1, both of which were improved in
Cxcl5/ mice. Since CXCR2 is important for mobilization of
neutrophils from marrow, as well as migration into tissues, these
data suggest that large absolute amounts of CXCL1 and CXCL2
may impair accumulation of neutrophils through effects at
several levels. Further studies will be required to distinguish
the impact of these mechanisms in vivo. Furthermore, CXCR2
deficiency leads to neutrophil dysplasia (over 90% Gr-1+ cells
in the BM) (Cacalano et al., 1994), indicating that CXCR2
signaling contributes to homeostatic control of neutrophil
numbers in the BM, but also indicates that CXCR2 ligands other
than CXCL5 play a role in neutrophil homeostasis. Additionally,
since endothelial CXCR2 plays an important role in regulating
neutrophil influx in LPS-induced lung inflammation (Reutershan
et al., 2006) and lung epithelial cells may express CXCR2 as
well (Vanderbilt et al., 2003), CXCL5 may modulate neutrophil
transepithelial and transendothelial migration.
In summary, CXCL5 exhibits nonredundant properties with
respect to other ELR+ CXC chemokines that exert profoundImmunity 33, 106–117, July 23, 2010 ª2010 Elsevier Inc. 115
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CXCL5 in Chemokine Scavenging and Lung Infectioneffects on the inflammatory response. Considering the involve-
ment of CXCL5 in a variety of human inflammatory diseases
(Goodman et al., 1996; Kwon et al., 2005; Qiu et al., 2003,
2007; Zineh et al., 2008), Cxcl5/ mice and the mechanisms
revealed here may be useful to study the role of CXCL5 in the
pathogenesis and therapeutics of inflammatory diseases.
EXPERIMENTAL PROCEDURES
Mice
All experiments with mice were conducted in accordance with the Institutional
Animal Care and Use Committee of the Children’s Hospital of Philadelphia and
University of Pittsburgh.
LPS Inhalation Mouse Model
The LPS inhalation mouse model has been previously described (Jeyaseelan
et al., 2004). The mice were exposed to nebulized LPS (0.3 mg/ml) for 30 min.
E. coli Pneumonia in the Mouse
The procedures for E. coli pneumonia mouse model have been previously
described (Jeyaseelan et al., 2005b).
Coagulation-Negative Bleed
The murine plasma samples without coagulation were prepared as described
(Sommeijer et al., 2005). In brief, after anesthetization, 3.2% (w/v) sodium
citrate in a total volume of body weight (gram)/13 3 100 ml was intravenously
administered into the vena cava 20–30 s to prevent coagulation prior to blood
drawing from the same vein into a syringe.
Competitive Chemokine Binding Assays
The competitive chemokine binding assays were performed as modified from
previousprotocols (Darbonneetal.,1991;Leeetal.,2003;Mangalmurti etal.,2009).
Measurement of Erythrocyte DARC-Binding Chemokines
This approach was modified from two previous reports (Reutershan et al.,
2009; Rot and Horuk, 2009).
Chemokine Scavenging Assay In Vitro
Thecitratedbloodwasdrawn frommiceasdescribedabove.25ngmurineCXCL5
(74 aa, from R&D), 25 ng CXCL1 (77 aa, from R&D), or 10 ng CXCL2 (from R&D)
in 10 ml PBS were put into 0.4 ml citrated blood and incubated at 37C for
15minafter beingmixed gently; then theplasmawere preparedby centrifugation.
Chemokine Clearance Assay In Vivo
1 mg murine CXCL5 (74 aa, from R&D), 1 mg murine CXCL1 (77 aa, from R&D),
or 0.5 mg murine CXCL2 (from R&D) in 50 ml PBS were intravenously injected
into the tail vein of WT and Cxcl5/mice. At different time points, the citrated
blood was drawn from the vena cava and the plasma samples were prepared.
Competitive Chemokine Binding Assays
In brief, purifiedmurine red cells fromWTorDarc/mice at 108 cells/well were
incubated in a volume of 0.25 ml containing 0.2 nM 125I-Gro-a/hCXCL1 or 125I-
hCCL2 (PerkinElmer) in the presence or absence of increasing molar concen-
trations of unlabeled chemokines. Recombinant CXCL5-70, CXCL1, CXCL2,
and CXCL5-93 are from Peprotech Inc. The mixture was incubated for
30 min on ice, and the reaction terminated by centrifuging the mixture through
a 30% sucrose cushion. The supernatant and sucrose fractions were sucked
off, and the remaining red cell pellet was measured in gamma counter.
Statistical Analyses
We performed statistical analyses with the GraphPad Prism software (version
4). Data are presented as means ± SEM. We used two-way ANOVA or
Student’s t test as appropriate to compare data sets.
Additional Experimental Procedures
All detailed experimental procedures are described in Supplemental
Information.116 Immunity 33, 106–117, July 23, 2010 ª2010 Elsevier Inc.SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures and Supplemental
Experimental Procedures and can be found with this article online at
doi:10.1016/j.immuni.2010.07.009.
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